MX2016005764A - Formulacion en suspension acuosa que comprende nanoparticulas de antibioticos macrolidos. - Google Patents

Formulacion en suspension acuosa que comprende nanoparticulas de antibioticos macrolidos.

Info

Publication number
MX2016005764A
MX2016005764A MX2016005764A MX2016005764A MX2016005764A MX 2016005764 A MX2016005764 A MX 2016005764A MX 2016005764 A MX2016005764 A MX 2016005764A MX 2016005764 A MX2016005764 A MX 2016005764A MX 2016005764 A MX2016005764 A MX 2016005764A
Authority
MX
Mexico
Prior art keywords
aqueous suspension
antibacterial agent
nanoparticles
suspension preparation
macrolide antibacterial
Prior art date
Application number
MX2016005764A
Other languages
English (en)
Inventor
Takahiro Tada
Kenta Kikuchi
Kazuhiro Kagami
Shiro Yokota
Original Assignee
Activus Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Activus Pharma Co Ltd filed Critical Activus Pharma Co Ltd
Publication of MX2016005764A publication Critical patent/MX2016005764A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

[Problema] El propósito de la presente invención es proporcionar una preparación en suspensión acuosa que comprende un antibacteriano macrólido como componente activo. Específicamente, el propósito de la presente invención es proporcionar una composición farmacéutica que comprende un antibacteriano macrólido como componente activo y que puede tener uso práctico. [Solución] La presente invención proporciona: una preparación en suspensión acuosa caracterizada porque comprende nanopartículas de un antibacteriano macrólido y un estabilizante de dispersión; una suspensión acuosa en la que tamaño de partícula promedio de las nanopartículas es de 500 nm o menos y el tamaño de partícula D90 es 1500 nm o menos; una composición farmacéutica administrada por vía parenteral que comprende esta preparación en suspensión acuosa; una preparación inyectable; y colirio o gotas óticas, en términos más específicos, colirio para el tratamiento o prevención de enfermedades inflamatorias del ojo o gotas óticas para el tratamiento o prevención de enfermedades inflamatorias del oído.
MX2016005764A 2013-11-08 2014-11-07 Formulacion en suspension acuosa que comprende nanoparticulas de antibioticos macrolidos. MX2016005764A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013231796 2013-11-08
PCT/JP2014/005603 WO2015068397A1 (ja) 2013-11-08 2014-11-07 マクロライド系抗菌剤のナノ微粒子を含有する水性懸濁液剤

Publications (1)

Publication Number Publication Date
MX2016005764A true MX2016005764A (es) 2017-01-05

Family

ID=53041191

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005764A MX2016005764A (es) 2013-11-08 2014-11-07 Formulacion en suspension acuosa que comprende nanoparticulas de antibioticos macrolidos.

Country Status (13)

Country Link
US (1) US10792248B2 (es)
EP (1) EP3067045A4 (es)
JP (1) JP6407882B2 (es)
KR (2) KR20160079781A (es)
CN (1) CN105658203B (es)
AU (1) AU2014345193C1 (es)
BR (1) BR112016010358B1 (es)
CA (1) CA2929361C (es)
IL (1) IL245406B (es)
MX (1) MX2016005764A (es)
RU (1) RU2707748C2 (es)
TW (3) TWI747209B (es)
WO (1) WO2015068397A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160079781A (ko) * 2013-11-08 2016-07-06 액티버스 파마 컴퍼니 리미티드 매크롤라이드계 항균제의 나노미립자를 함유하는 수성 현탁액제
WO2020223158A1 (en) * 2019-04-30 2020-11-05 The Medical College Of Wisconsin, Inc. Trans-tympanic membrane delivery platform and uses thereof
CN113484436B (zh) * 2021-07-06 2022-07-12 云南中烟工业有限责任公司 同时测定抑菌纸张中五种禁限用物质含量的方法及其用途
US20230226541A1 (en) * 2022-01-18 2023-07-20 Hollister Incorporated Fluid absorption test tube
WO2023229667A1 (en) * 2022-05-24 2023-11-30 The Cleveland Clinic Foundation Topical angiotensin ii receptor blockers (arbs) for treating eye conditions
CN116686841B (zh) * 2023-06-07 2024-07-19 丽珠集团新北江制药股份有限公司 一种含有多烯烃大环内酯类物质的液态组合物的制备方法
WO2024121651A1 (en) * 2023-11-10 2024-06-13 Amiri ِAmir Ali A liquid herbal antibiotic and a powder herbal antibiotic containing a herbal antibacterial formulation

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2577742B2 (ja) * 1986-07-18 1997-02-05 中外製薬株式会社 安定な顆粒球コロニ−刺激因子含有製剤
NZ233827A (en) 1989-05-26 1991-06-25 Abbott Lab Pharmaceutical composition comprising clarithromycin, triglyceride oil and stabilising agent
AU6461090A (en) 1989-10-30 1991-05-02 Abbott Laboratories Injectable formulation for lipophilic drugs
US5085864A (en) 1989-10-30 1992-02-04 Abbott Laboratories Injectable formulation for lipophilic drugs
JP2785981B2 (ja) * 1989-11-20 1998-08-13 株式会社資生堂 乳化組成物
US7205279B2 (en) * 1995-10-25 2007-04-17 Novartis Ag Pharmaceutical compositions
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
JP2001511780A (ja) * 1997-02-04 2001-08-14 アボツト・ラボラトリーズ 鎮痛性非経口リポソーム配合物
US7056893B2 (en) * 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US20030195179A1 (en) 2000-08-25 2003-10-16 Shirou Sawa Aqueous suspension preparations
CA2492488A1 (en) 2002-07-16 2004-01-22 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
US7220431B2 (en) 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
CA2591744A1 (en) * 2004-12-21 2006-06-29 Pfizer Products Inc. Stable non-dihydrate azithromycin oral suspensions
US20070015719A1 (en) * 2005-07-07 2007-01-18 Elan Pharma International Limited Nanoparticulate clarithromycin formulations
JP5112669B2 (ja) * 2005-09-30 2013-01-09 富山化学工業株式会社 難溶性薬物のナノ微粒子を含有する水性懸濁液剤
WO2007056205A2 (en) * 2005-11-04 2007-05-18 Eastman Chemical Company Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
PL2076244T3 (pl) * 2006-10-10 2017-05-31 Jina Pharmaceuticals Inc. Układy wodne do wytwarzania związków farmaceutycznych na bazie lipidów; kompozycje, sposoby, oraz ich zastosowanie
US20100068251A1 (en) * 2006-10-10 2010-03-18 Jina Pharmaceuticals, Inc. Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof
TWI405590B (zh) 2007-04-06 2013-08-21 Activus Pharma Co Ltd 微粉碎化有機化合物粒子之製法
US20080160043A1 (en) * 2007-07-16 2008-07-03 Kim Moo-Sung Preparation method of beta-glucan from schizophyllum commune and composition for external application comprising the same
WO2009029046A1 (en) * 2007-08-29 2009-03-05 Agency For Science, Technology And Research Sugar-based surfactant microemulsions containing essential oils for cosmetic and pharmaceutical use
CN102099013A (zh) 2008-07-14 2011-06-15 奥德纳米有限公司 用于治疗耳部病症的控制释放凋亡调节组合物和方法
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
EP2335686A1 (en) * 2009-12-21 2011-06-22 LEK Pharmaceuticals d.d. An aqueous intravenous nanosuspension with reduced adverse effects
MX341663B (es) 2012-05-11 2016-08-30 Activus Pharma Co Ltd Nanopolvo de compuesto organico, metodo para producirlo y su suspension.
KR20160079781A (ko) * 2013-11-08 2016-07-06 액티버스 파마 컴퍼니 리미티드 매크롤라이드계 항균제의 나노미립자를 함유하는 수성 현탁액제

Also Published As

Publication number Publication date
TW201828923A (zh) 2018-08-16
KR20160079781A (ko) 2016-07-06
TWI747209B (zh) 2021-11-21
JPWO2015068397A1 (ja) 2017-03-09
RU2707748C2 (ru) 2019-11-29
CN105658203B (zh) 2021-03-16
BR112016010358A2 (es) 2017-08-08
AU2014345193A1 (en) 2016-06-02
KR20210054068A (ko) 2021-05-12
US20160271057A1 (en) 2016-09-22
EP3067045A1 (en) 2016-09-14
CN105658203A (zh) 2016-06-08
US10792248B2 (en) 2020-10-06
BR112016010358B1 (pt) 2022-07-26
EP3067045A4 (en) 2016-11-16
TW201521785A (zh) 2015-06-16
AU2014345193C1 (en) 2020-09-10
CA2929361C (en) 2022-05-31
CA2929361A1 (en) 2015-05-14
WO2015068397A1 (ja) 2015-05-14
RU2016122544A (ru) 2017-12-13
IL245406A0 (en) 2016-06-30
IL245406B (en) 2021-03-25
RU2016122544A3 (es) 2018-05-29
KR102345084B1 (ko) 2021-12-29
TW202027726A (zh) 2020-08-01
TWI691341B (zh) 2020-04-21
AU2014345193B2 (en) 2020-03-05
JP6407882B2 (ja) 2018-10-17

Similar Documents

Publication Publication Date Title
MX2016005764A (es) Formulacion en suspension acuosa que comprende nanoparticulas de antibioticos macrolidos.
MX2021007794A (es) Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.
MX2017014340A (es) Suspension acuosa que contiene nanoparticulas de glucocorticosteroide.
MX2020007227A (es) Nanoparticulas farmaceuticas que muestran la mejora del transporte de la mucosa.
PH12015502587B1 (en) Ophthalmic nanoemulsion composition containing cyclosporine and method for preparing same
AU2018256591A1 (en) Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
MX370853B (es) Formulaciones que contienen dapagliflozina amorfa.
PH12019501902A1 (en) Ocular formulations for drug-delivery to the posterior segment of the eye
GB2491328A (en) Immediate/delayed drug delivery
CO7310520A2 (es) Nanopartícula polimérica de finasterida y minoxidil proceso de preparación, suspensión acuosa conteniendo la misma,composición farmaceútica y su uso
MX2017009699A (es) Composicion de suspension oftalmica.
NZ705985A (en) Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
MX2019003467A (es) Formulaciones y metodos para la administracion vaginal de antiprogestinas.
NZ704247A (en) Compositions and treatment for eye diseases and disorders
PH12019550088A1 (en) Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
NZ719185A (en) Crystalline forms of therapeutic compounds and uses thereof
MX2015010083A (es) Nanoparticulas biodegradables y clinicamente compatibles como portadores para administracion de farmacos.
PH12017502155A1 (en) Formation of cyclosporin a/cyclodextrin nanoparticles
MY196111A (en) Suspension Compositions of Cyclosporin a for Subconjunctival and Periocular Injection
MX2019010852A (es) Nanoparticulas a base de lipidos con estabilidad mejorada.
MX2016015208A (es) Nanoparticulas de clevidipina y composiciones farmaceuticas que las contienen.
MX2018004445A (es) Particulas coloidales para su uso en medicina.
WO2013038195A3 (en) Pharmaceutical nanoparticle compositions
WO2012123924A3 (en) Antimicrobial composition including at least one or more aggregation(s) silver particles
WO2015079415A9 (en) Amorphous cobicistat solid dispersion